Diagnostic yield of genetic tests in epilepsy
A meta-analysis and cost-effectiveness study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 8, 2018
- Accepted in final form August 30, 2018
- First Published January 4, 2019.
Article Versions
- Previous version (January 4, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Iván Sánchez Fernández, MD, MPH,
- Tobias Loddenkemper, MD,
- Marina Gaínza-Lein, MD,
- Beth Rosen Sheidley, MS, CGC and
- Annapurna Poduri, MD, MPH
- Iván Sánchez Fernández, MD, MPH,
NONE
NONE
NONE
(1) Seizure, the European Journal of Epilepsy. Guest Editor for the Special Issue "Pediatric Convulsive Status Epilepticus". 2017-2018. No economic compensation.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Epilepsy Research Fund, (2) Fundacin Alfonso Martn Escudero (Grant for the study of Epileptic Encephalopathies), (3) HHV6 Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Loddenkemper, MD,
Tobias Loddenkemper serves on the Council (and as President) of the American Clinical Neurophysiology Society, on the American Board of Clinical Neurophysiology, as committee chair at the American Epilepsy Society (Special Interest Group and Investigator Workshop Committees), as founder and consortium PI of the pediatric status epilepticus research group (pSERG),
NONE
Travel support to give grand rounds and lectures at several academic institutions, and at scientific meetings including AAN, AES, and ACNS as well as international meetings.
serves as an Associate Editor for Wyllie?s Treatment of Epilepsy 6th and 7th editions,
has submitted pending/approved patents for epilepsy diagnosis and seizure detection, as well as seizure prediction. Dr. Loddenkemper is co-inventor of the TriVox Health technology. In the future it is possible that this technology will be sold commercially. If this were to occur, Dr. Loddenkemper, and Boston Children?s Hospital might receive financial benefits in the form of compensation. As in all research studies, the hospital has taken steps designed to ensure that this potential for financial gain does not endanger research subjects or undercut the validity and integrity of the information learned by this research.
NONE
NONE
He serves as a consultant for Zogenix, Engage, Amzell, Upsher Smith, Eisai, and Sunovion.
NONE
has received travel support for non-commercial academic presentations, symposia, and grand rounds nationally and internationally,
performs Video EEG longterm monitoring, EEGs, and other electrophysiological studies at Boston Children's Hospital and bills for these procedures, evaluated pediatric neurology patients and bills for clinical care,
received research grants from Lundbeck, Eisai, Upsher- Smith, Sunovion, Mallinckrodt, Sage, and Pfizer,
NIH,
Boston Children's Hospital and Harvard Medical School
Epilepsy Research Fund, the Epilepsy Foundation of America, the Epilepsy Therapy Project, the Pediatric Epilepsy Research Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Marina Gaínza-Lein, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Marina Gaiínza-Lein was funded by a Boston Children?s Hospital investigator-initiated study from Upsher-Smith Laboratories.
NONE
NONE
(1) Marina Gaínza-Lein was funded by the Epilepsy Research Fund.
NONE
NONE
NONE
NONE
NONE
NONE
- Beth Rosen Sheidley, MS, CGC and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Annapurna Poduri, MD, MPH
(1) Dravet Syndrome Foundation (2) Tevard Bio
NONE
NONE
(1) Epilepsia, Associate Editor (Genetics), 2013-present (2) Epilepsy Currents, Contributing Editor, 2013-present (3) Annals of Neurology, Editorial Board member, 2015- present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Zogenix (fenfluramine trial)
NINDS (R01NS094596), Co-I 2016-present NICHD (U24HD093487), Co-PI, 2017-present NINDS (R01NS100766), PI, 2017-present
During the period of the study, I was supported by the Boston Children's Hospital Translational Research Program.
(1) Charles H. Hood Foundation (2) Tommy Fuss Center Innovation Program, Boston Children's Hospital (3) Citizens United for Research in Epilepsy
NONE
NONE
NONE
NONE
NONE
NONE
- From the Epilepsy Genetics Program (B.R.S., A.P.), Division of Epilepsy and Clinical Neurophysiology (I.S.F., T.L., M.G.-L., B.R.S., A.P.), Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA; Department of Child Neurology (I.S.F.), Hospital Sant Joan de Déu, Universidad de Barcelona, Spain; and Facultad de Medicina (M.G.-L.), Universidad Austral de Chile, Valdivia.
- Correspondence
Dr. Poduri annapurna.poduri{at}childrens.harvard.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticusIván Sánchez Fernández, Marina Gaínza-Lein, Nathan Lamb et al.Neurology, May 08, 2019 -
Article
Genetic landscape of pediatric movement disorders and management implicationsDawn Cordeiro, Garrett Bullivant, Komudi Siriwardena et al.Neurology: Genetics, September 26, 2018 -
Article
Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the USShehryar R. Sheikh, Michael W. Kattan, Michael Steinmetz et al.Neurology, July 08, 2020 -
Articles
The cost-effectiveness of telestroke in the treatment of acute ischemic strokeR.E. Nelson, G.M. Saltzman, E.J. Skalabrin et al.Neurology, September 14, 2011